Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Codexis Inc (CDXS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,062,600
  • Shares Outstanding, K 54,159
  • Annual Sales, $ 60,590 K
  • Annual Income, $ -10,880 K
  • 60-Month Beta -0.31
  • Price/Sales 18.66
  • Price/Cash Flow N/A
  • Price/Book 20.03

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.09
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.13
  • Prior Year -0.10
  • Growth Rate Est. (year over year) +10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
19.05 +2.99%
on 03/05/19
22.25 -11.82%
on 02/25/19
-2.25 (-10.29%)
since 02/22/19
3-Month
15.31 +28.15%
on 12/24/18
22.49 -12.76%
on 02/13/19
+3.69 (+23.16%)
since 12/21/18
52-Week
9.30 +110.97%
on 04/06/18
23.05 -14.88%
on 12/03/18
+8.07 (+69.87%)
since 03/22/18

Most Recent Stories

More News
Codexis (CDXS) Q4 Earnings Beat Estimates

Codexis (CDXS) delivered earnings and revenue surprises of 400.00% and -3.34%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

CDXS : 19.62 (-6.03%)
Codexis to Participate in Two Investment Conferences in March

Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in two upcoming investment conferences:

CDXS : 19.62 (-6.03%)
Analysis: Positioning to Benefit within Synchrony Financial, KKR & Co., Life Storage, Unum Group, Codexis, and Finisar -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Synchrony Financial (NYSE:SYF),...

SYF : 31.83 (-3.28%)
KKR : 23.66 (-3.51%)
LSI : 95.54 (-0.56%)
CDXS : 19.62 (-6.03%)
UNM : 33.37 (-3.61%)
FNSR : 22.86 (-2.60%)
Codexis Reports 2018 Fourth Quarter and Full Year Financial Results

2018 revenues of $61 million include a 50% increase in R&D revenue

CDXS : 19.62 (-6.03%)
Codexis Names Laurie Heilmann Senior Vice President of Business Development and Marketing

Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the appointment of Laurie Heilmann to Senior Vice President of Business Development and Marketing. Heilmann brings to Codexis...

CDXS : 19.62 (-6.03%)
Codexis to Hold 2018 Fourth Quarter and Full Year Conference Call on February 26

Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report 2018 fourth quarter and full year financial results after market close on Tuesday, February 26, 2019....

CDXS : 19.62 (-6.03%)
Codexis Announces Nestle Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria

Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that Nestle Health Science has exercised its option to obtain an exclusive license for the global development and commercialization...

CDXS : 19.62 (-6.03%)
Codexis Announces Enzyme Supply Agreement with KYORIN Pharmaceutical for Overactive Bladder Drug Sold in Japan

Codexis, Inc. (NASDAQ: CDXS) announces a multi-year, exclusive supply agreement with KYORIN Pharmaceutical Co., Ltd. for the supply of a proprietary enzyme to be used in the manufacture of vibegron, an...

CDXS : 19.62 (-6.03%)
Codexis Secures Multi-Year Technology Upgrade Package for its CodeEvolver Protein Engineering Platform License with Merck

Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a new agreement with Merck, through a subsidiary. Under the terms of the agreement, Codexis will install certain...

CDXS : 19.62 (-6.03%)
MRK : 82.29 (-0.80%)
Cimpress Aims to Mitigate Risks by Decentralizing Operations

Cimpress' (CMPR) management has decentralized operations to improve accountability for customer satisfaction and capital returns, simplify decision-making and improve the speed of execution.

CMPR : 74.78 (-4.47%)
CDXS : 19.62 (-6.03%)
KIGRY : 13.3900 (-6.69%)
HDS : 41.71 (-2.73%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Trade CDXS with:

Business Summary

Codexis is a leading protein engineering company that applies its proprietary CodeEvolver technology to develop proteins for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and...

See More

Key Turning Points

2nd Resistance Point 21.34
1st Resistance Point 20.48
Last Price 19.62
1st Support Level 19.19
2nd Support Level 18.75

See More

52-Week High 23.05
Last Price 19.62
Fibonacci 61.8% 17.80
Fibonacci 50% 16.17
Fibonacci 38.2% 14.55
52-Week Low 9.30

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar